Citations

Clear

361 citation(s) found for "Bauer, M".

P4‐298: IMPROVING THE POWER TO TRACK FIBRILLAR AMYLOID PET MEASUREMENTS AND EVALUATE AMYLOID‐MODIFYING TREATMENTS USING A CEREBRAL WHITE MATTER REFERENCE REGION‐OF‐INTEREST
Roontiva, Auttawut, Lee, Wendy , Ayutyanont, Napatkamon , Protas, Hillary , Landau, Susan , Luo, Ji , Bauer, Robert, Reschke, Cole, Bandy, Dan, Fleisher, Adam , Caselli, Richard J., Jagust, William J. , Weiner, Michael W. , Reiman, Eric M. , Chen, Kewei , Thiyyagura, Pradeep , Liu, Xiaofen , Koeppe, Robert A. , Caselli, Richard J.

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_15 | Pages: No page available

10.1016/j.jalz.2014.07.069 Get It

P2‐141: BRAIN‐DERIVED NEUROTROPHIC FACTOR (BDNF) POLYMORPHISMS ARE ASSOCIATED WITH DIFFERENTIAL RATES OF AMYLOID ACCUMULATION AND COGNITIVE DECLINE IN COGNITIVELY NORMAL OLDER ADULTS
Acosta, Jazmin I., Fleisher, Adam , Reschke, Cole, Bauer, Robert, Caselli, Richard J., Weiner, Michael W. , Reiman, Eric M. , Geda, Yonas E. , Stokin, Gorazd B. , Thiyyagura, Pradeep , Lu, Bai , Caselli, Richard J. , Chen, Kewei

Mayo Clinic

Alzheimer's & Dementia | September 6, 2014 | Volume: 10 | Issue: 4S_Part_13 | Pages: No page available

10.1016/j.jalz.2014.05.816 Get It

Medical Students Familiarity, Experience and Attitudes Towards Complementary and Alternative Medicine
Wahner‐Roedler, Dietlind L. , Loehrer, Laura L., Cha, Stephen , Bauer, Brent A.

Mayo Clinic

The Journal of Alternative and Complementary Medicine | May 7, 2014 | Volume: 20 | Issue: 5 | Pages: A77-A77

10.1089/acm.2014.5202.abstract Get It

Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia
Pflug, Natali , Bahlo, Jasmin, Eichhorst, Barbara , Bergmann, Manuela A., Elter, Thomas , Bauer, K. H. , Malchau, Gebhart, Rabe, Kari G. , Jäger, Ulrich, Eckart, Michael J., Busch, Raymonde, Fink, Anna‐Maria , Wendtner, Clemens‐Martin , Fischer, Kirsten , Hallek, Michael , Shanafelt, Tait D. , Stilgenbauer, Stephan , Döhner, Hartmut , Hopfinger, Georg , Kay, Neil E. , Chaffee, Kari G.

Mayo Clinic

Blood | May 6, 2014 | Volume: 124 | Issue: 1 | Pages: 49-62

10.1182/blood-2014-02-556399 | PMID 24797299 Get It

Key PointsPrognostic tool for CLL patients with high discriminatory power compared with conventional clinical staging systems. Prognostication on the individual patient level independent of clinical stage.
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib
Joensuu, Heikki , Hartmann, Jörg T., Pink, Daniel , Schütte, J., Ramadori, Giuliano , Hohenberger, Peter , Duyster, Justus , Al‐Batran, Salah‐Eddin, Schlemmer, M., Bauer, Sebastian , Sarlomo‐Rikala, Maarit, Nilsson, Bengt, Sihto, Harri , Ballman, Karla V. , Leinonen, Mika, DeMatteo, Ronald P. , Reichardt, Peter , Eriksson, Mikael , Hall, Kirsten Sundby , Al-Batran, Salah Eddin, Wardelmann, Eva , Joensuu, Heikki , Ballman, Karla , Bauer, Sebastian

Mayo Clinic

Cancer | April 15, 2014 | Volume: 120 | Issue: 15 | Pages: 2325-2333

10.1002/cncr.28669 | PMID 24737415 Get It

BACKGROUNDLittle is known about the factors that predict for gastrointestinal stromal tumor (GIST) recurrence in patients treated with adjuvant imatinib.METHODSRisk factors for GIST recurrence were identified, and 2 risk stratification scores were developed using the database of the Scandinavian Sarcoma Group (SSG) XVIII trial, where 358 patients with high‐risk GIST with no overt metastases were randomly assigned to adjuvant imatinib 400 mg/day either for 12 or 36 months after surgery. The findings were validated in the imatinib arm of the American College of Surgeons Oncology Group Z9001 trial, where 359 patients with GIST were randomized to receive imatinib and 354 were to receive placebo for 12 months.RESULTSFive factors (high tumor mitotic count, nongastric location, large size, rupture, and adjuvant imatinib for 12 months) were independently associated with unfavorable recurrence‐free survival (RFS) in a multivariable analysis in the SSGXVIII cohort. A risk score based on these 5 factors had a concordance index with GIST recurrence of 78.9%. When a simpler score consisting of the 2 strongest predictive factors (mitotic count and tumor site) was devised, the groups with the lowest, intermediate high, and the highest risk had 5‐year RFS of 76.7%, 47.5%, and 8.4%, respectively. Both scores were strongly associated with RFS in the validation cohort (P < .001 for each comparison).CONCLUSIONSThe scores generated were effective in stratifying the risk of GIST recurrence in patient populations treated with adjuvant imatinib. Patients with nongastric GIST with a high mitotic count are at a particularly high risk for recurrence. Cancer 2014;120:2325–2333 © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society.
Microscopic Examination of Iatrogenic Subglottic Tracheal Stenosis
Welkoborsky, Hans-J., Hinni, Michael L., Moebius, Hartmut, Bauer, Lothar, Ostertag, Helmut

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | February 27, 2014 | Volume: 123 | Issue: 1 | Pages: 25-31

10.1177/0003489414521382 | PMID 24574420 Get It

Objectives: The histopathologic origin of iatrogenic subglottic tracheal stenosis (ISTS) remains unclear. The purpose of this study was to use detailed operative microscopy to systematically examine the operative en bloc specimens of patients with ISTS and to observe the histologic and morphological changes in the hopes that these observations will provide insight into the histopathologic origin of these devastating injuries. Methods: The operative specimens of 18 patients who underwent open tracheal or laryngotracheal resection for ISTS were examined. Precise morphological characteristics were investigated for each tissue layer, including the adventitia, the outer surface of the perichondrium, the cartilage, the inner surface of the perichondrium, the submucosa, and the mucosa. Each tissue layer was evaluated independently and in relationship to the other layers. The cartilaginous airway was further evaluated relative to the pars membranacea. Results: The most common morphological finding in the epithelium was squamous metaplasia with occasional intense inflammation visible in the underlying mucosa, including cicatrization. The underlying cartilage demonstrated ossific metaplasia with sequestration in many cases. By far the most pronounced changes were found in the outer perichondrium and overlying adventitia and included diffuse paucicellular or hyperplastic fibrosis with intense hyperplastic scar formation or hyaline cicatrization. In the pars membranacea, severe scar formation and hyperplastic fibrosis were predominant. Ossific metaplasia was particularly severe in the lateral or outer parts of the tracheal ring, particularly in the vicinity of the adventitia and outer perichondrium. These changes were much more pronounced than the relatively minor changes observed in the submucosa and mucosa. Conclusions: The most severe pathologic observations occurred in the lateral tissue layers, ie, the outer perichondrium and adventia. Given that an injury occurs from the tracheal lumen, these tissue layers have the greatest distance from the site of injury. As only minor changes occurred in the inner tissue layers, we hypothesize that these tissues have a greater regenerative capacity than the outer layers. This study supports the theory that the depth of the airway injury is more critical to the development of ISTS than is the extent or length of the injury.
DT‐01–06: Baseline FDG‐PET and volumetric MRI predicts Alzheimer's disease conversion from mild cognitive impairment: An ADNI study
Stonnington, Cynthia M. , Ayutyanont, Napatkamon , Reschke, Cole, Thyyagura, Pradeep, Protas, Hillary , Roontiva, Auttawut, Parks, Stephanie, Bauer, Robert, Lee, Wendy , Jagust, William, Foster, Norman L. , Weiner, Michael W. , Fleisher, Adam , Reiman, Eric M. , Chen, Kewei , Liu, Xiaofen , Koeppe, Robert A.

Mayo Clinic

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_21 | Pages: No page available

10.1016/j.jalz.2013.08.007 Get It